Palatin Technologies INC Stock: price and insider trades · United States · SEC (Form 4)

About Palatin Technologies INC

Palatin Technologies Inc. (ticker PTN) is a U.S.-based biopharmaceutical company quoted on the NYSE American market in the United States, with its main executive office in Princeton, New Jersey. For French-speaking investors, Palatin is best understood as a specialty clinical-stage biotech focused on the melanocortin receptor system, a biological pathway that influences appetite, metabolism, inflammation, and certain immune responses. The company positions itself as a developer of first-in-class medicines aimed at diseases with meaningful unmet medical need and commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm)) Palatin was founded in the 1990s and has built a long-standing niche around melanocortin biology. Its leadership has been remarkably stable, with co-founder and CEO Carl Spana serving in senior management for decades. The company’s core strategy is typical of a development-stage biotech: advance internally generated assets through preclinical and clinical milestones, then seek to create value through strategic collaborations, licensing agreements, or other partnering arrangements with larger pharmaceutical groups. ([palatin.com](https://palatin.com/about-us/?utm_source=openai)) The current pipeline is centered on MC4R agonists, including peptides and small molecules designed for obesity, metabolic disorders, and rare MC4R-pathway diseases such as hypothalamic obesity and Prader-Willi syndrome. Palatin is also developing MC1R agonist programs with potential applications in inflammatory and autoimmune diseases, including dry eye disease, uveitis, diabetic retinopathy, and inflammatory bowel disease. Historically, the company also had a commercial product, Vyleesi®, which was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women; however, that asset was divested to Cosette Pharmaceuticals in 2023. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm)) From a competitive standpoint, Palatin remains a small-cap, high-risk, high-upside biotech rather than a commercial-stage pharmaceutical company. Its investment case depends on the scientific and clinical differentiation of its melanocortin platform versus much larger competitors active in obesity, ophthalmology, and immunology. The upside is that Palatin’s approach is targeted and potentially novel; the downside is the usual biotech constraints: limited resources, clinical/regulatory uncertainty, and the need for repeated external financing. The company’s most recent annual report explicitly highlights accumulated losses, modest cash balances, and the need for additional capital to continue its development plan. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm)) Recent news has been constructive at the program level. Palatin has been advancing PL7737, an oral MC4R agonist for obesity, with IND and clinical initiation plans outlined for 2026, and it announced a global research collaboration and license agreement with Boehringer Ingelheim in August 2025 aimed at retinal disease. The company also completed multiple equity financings to support operations and, according to its filings, experienced listing and trading changes during 2025, including a period on OTCQB after the NYSE American listing was interrupted. ([palatin.com](https://palatin.com/press_releases/?utm_source=openai))